Early Access — free while we kick the tires
EdgarHawk

Llc Sr One Capital Management

10% Owner

10% Owner

Latest: Insider buying · May 2026

4 filings analyzed · 3 companies · Latest 2026-05-11

Companies

Company Buys Sells Direction
Odyssey Therapeutics, Inc. ODTX 21 0 Net buying
Avalyn Pharma Inc. AVLN 6 0 Net buying
Zenas BioPharma, Inc. ZBIO 8 0 Net buying

Activity

May 2026
2026-05-11 Odyssey Therapeutics, Inc. ODTX Cluster
high
Buy
555,555 shares
$9,999,990
Significance 7/10

10% owner Llc Sr One Capital Management purchases ~3.8M shares in bulk transactions; part of 5-insider buying cluster within two weeks.

Llc Sr One Capital Management, a ten-percent institutional holder, executed three large open-market purchases totaling approximately $10 million in aggregate value on a single day, acquiring nearly 3.8 million shares net. This activity is part of a broader pattern: five insiders bought shares within a two-week window, indicating sustained buying interest from multiple parties at the company level. The purchases occurred when the stock was trading above its initial trading reference point, suggesting the institutional buyer is willing to accumulate at these levels rather than wait for pullbacks. Historically, this institutional holder has favored buying over selling, with seven prior open-market purchases on record; however, its past buy transactions showed strong short-term gains but deteriorated sharply over longer horizons, with zero wins at the 90-day mark. The current cluster activity and scale of this purchase merit attention, though the institutional nature of the filer means these trades reflect portfolio allocation decisions rather than insider knowledge of material developments.

2026-05-01 Avalyn Pharma Inc. AVLN
high
Buy
555,555 shares
$9,999,990
Significance 7/10

SR ONE CAPITAL MANAGEMENT buys 555,555 shares ($9,999,990) at $18.00; holdings nearly double to 1.12M in 2-day-old listing

SR ONE CAPITAL MANAGEMENT, a 10% shareholder, executed 2 separate purchases totaling 555,555 shares for $9,999,990.00 at $18.00 on 2026-05-01, doubling its stake from 566,532 shares to 1,122,087 shares (a +98.1% increase). The transaction occurred on a RECENT LISTING stock (2 trading days post-IPO), where the current market price of $29.84 represents a 65.8% premium to the purchase price, though meaningful historical context is unavailable at this stage. A CLUSTER pattern is present: 2 other insiders also bought within the past 14 days, indicating coordinated conviction at the board/executive level. The DERIVATIVE-CONVERSION FLAG indicates this filing contains a conversion of derivative securities, and the insider's full position resides in Table II (not yet populated in our database), so the post-transaction figure of 1.12M shares does not necessarily represent the insider's total economic position.

October 2025
2025-10-14 Zenas BioPharma, Inc. ZBIO
medium
Buy
126,315 shares
$2,399,985
Significance 5/10

10% owner SR ONE CAPITAL MANAGEMENT buys 126,315 shares at $19.00 (+$2.4M) as stock rallies 27.8% in 30 days

SR ONE CAPITAL MANAGEMENT, LLC, a 10% shareholder, executed 2 separate purchases totaling 126,315 shares for $2,399,985.00 at $19.00 per share on 2025-10-09, increasing holdings from 1,791,580 to 1,917,895 shares (+7.1% relative to pre-transaction holdings). The purchase occurred after the stock gained 27.8% over the prior 30 days and 97.8% over 90 days, placing it 6.9% below its 52-week high. However, this insider's prior 3 purchases at ZBIO share a concerning pattern: each yielded 14.6% gains at 30 days but -47.5% losses at 90 days, with 0 of 3 prior buys proving well-timed at the 90-day mark. Additionally, the company faces material headwinds: zero quarterly revenue, a $-52,223,000 net loss in the most recent quarter, and a -90.0% annual revenue decline. The acquisition coincides with a cluster pattern in which 5 other insiders also bought within the past 14 days, suggesting coordinated accumulation at elevated momentum levels rather than contrarian positioning.

September 2024
2024-09-16 Zenas BioPharma, Inc. ZBIO
high
Buy
2,235,294 shares
$37,999,998
Significance 7/10

10% owner SR ONE CAPITAL MANAGEMENT bought 2,235,294 shares for $37,999,998.00 at $17.00 on 2024-09-16; 5 other insiders also bought within 14 days

SR ONE CAPITAL MANAGEMENT, a 10% owner of Zenas BioPharma, executed 3 separate purchases totaling 2,235,294 shares for $37,999,998.00 at a blended average price of $17.00 on 2024-09-16, just 2 trading days after the company's recent listing. The transaction brought the filer's holdings to 1,110,237 shares post-transaction. This filing reflects a derivative-conversion transaction where the insider's complete economic position extends into Form 4 Table II (derivative securities), which remains unpopulated in the current database; accordingly, the Table I holdings do not represent the filer's total stake. A cluster buy pattern is evident: 5 other insiders also bought within the past 14 days, indicating coordinated capital deployment around the recent IPO/listing event. The substantial dollar commitment ($38.0M) at the listing price is a material signal of insider confidence at current valuation, though the timing is post-listing rather than a pre-listing or secondary accumulation pattern.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access